- 06 Jan 2018, 11:20
One stat that defines all the problem with Pharmacovigilance in India. Sun Pharmaceutical Industries Limited, which is the market leader in the Indian Pharmaceutical Market space reported only one (01) report of Adverse Drug Reaction with all its product for the month November-2017. Compare this to Novartis which reported 262 reports during the same duration, Pfizer reported 70, Bayer reported 135, Glaxo 37, and Roche 36.
Clearly home grown generic companies are either not taking pharmacovigilance too strictly or the reporters are missing out on reporting adverse events with generics. Or perhaps the old classical that reporting safety information for newer products is more important than safety information for generics/ established products.
PvPI ADRs Reporting Status–November, 2017
ADR - Pharma Companies.jpg (126.84 KiB) Viewed 4223 times
Find Me Here ---> ResearchGate, Scopus , Linkedin